The Patent Finder

Green Cross Corporation

40 patents currently held · Updated Nov 18, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

4
Ending by 2030
Mar 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Mar 10 to 17, 2027 · next Mar 10
  • 1 fee due Apr 15, 2027
    The maintenance fee for Kit for measuring titer of a protein comprising human Fc using indirect ELISA and method for measuring titer of a protein comprising human Fc using the same (US 10,444,246) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
  • 3 fees due Jun 1 to 8, 2027 · next Jun 1
  • 2 fees due Aug 2 to 18, 2027 · next Aug 2
  • 2 fees due Nov 5 to 17, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026
  • 2 terms have ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,519,108Method for Preparing Antigen Effective for Preventing Anthrax Infection
In force
 · High confidence
In forceHigh confidence
US 8,541,380C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,018,182Tumor-Specific Promoter and Oncolytic Virus Vector Comprising the Same
In force
 · High confidence
In forceHigh confidence
US 9,200,062Human Antibodies Specifically Binding to the Hepatitis B Virus Surface Antigen
In force
 · High confidence
In forceHigh confidence
US 8,754,210Method for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl) derivative and intermediate used therein
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,586,550Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,006,187Novel Thiophene Derivative as SGLT2 Inhibitor and Pharmaceutical Composition Comprising Same
In force
 · High confidence
In forceHigh confidence
US 9,034,921Novel Diphenylmethane Derivatives as SGLT2 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,371,303Diphenylmethane derivatives as SGLT2 inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,921,412C-aryl ansa SGLT2 inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 40 patents shown.
Pro members see all 40.
Pro members: see all 40 patents
Also on record, not counted in the 40: 3 patents in force now held by others · 18 lapsed for an unpaid fee · 228 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 5 abandoned · 27 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited